OR20-5 28-Day Dosing with Avexitide Improves Hyperinsulinemic Hypoglycemia in Patients with Severe, Refractory Post-Bariatric Hypoglycemia: The PREVENT Study

Avexitide (formerly exendin 9-39) is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist in development as a liquid formulation for subcutaneous (SC) injection for treatment of post-bariatric hypoglycemia (PBH). PBH, a rare disease with high unmet medical need and no approved pharma...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Endocr Soc
Asıl Yazarlar: Lee, Clare, Lawler, Helen, Tan, Marilyn, Davis, Dawn, Tong, Jenny, Glodowski, Michele, Rogowitz, Elisa, Lamendola, Cindy, Karaman, Rowan, Dar, Moahad, Porter, Lisa, Craig, Colleen
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Endocrine Society 2019
Konular:
Adipose Tissue, Appetite, and Obesity
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6554793/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-OR20-5
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller